| Dr Catherine Russell, PHD | |
|
215 Perry Hill Rd, Montgomery, AL 36109-3725 | |
| (334) 272-4670 | |
| Not Available |
| Full Name | Dr Catherine Russell |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 215 Perry Hill Rd, Montgomery, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134234347 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 1-042072 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Catherine Russell, PHD 447 Fredot Rd, Montgomery, AL 36105-3556 Ph: (334) 281-3326 | Dr Catherine Russell, PHD 215 Perry Hill Rd, Montgomery, AL 36109-3725 Ph: (334) 272-4670 |
News Archive
For some healthcare providers - especially those serving racial/ethnic minority and low-income patients - the costs of delivering a new Medicare Diabetes Prevention Program may be much higher than the expected reimbursement, reports a study in the November issue of Medical Care.
President-elect Joe Biden has signaled that fighting the COVID-19 pandemic will be an immediate priority for his administration. He recently announced a coronavirus advisory board of infectious disease researchers and former public health advisers along with an updated strategy that will include increases in testing and contact tracing, as well as transparent communication.
From staying hydrated to avoiding jet lag, Cooper Aerobics is making a commitment to help Flexjet owners prevent health issues while traveling. As part of its new alliance with Cooper Aerobics – a prestigious health and wellness center in Dallas – Flexjet, one of the world's leading fractional jet ownership services providers, has selected Founder and Chairman Kenneth Cooper, M.D., M.P.H., and CEO Tyler Cooper, M.D., M.P.H., as its official health advisors.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
› Verified 3 days ago
Laura L Rue, CRNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 273 Winton M Blount Loop, Montgomery, AL 36117 Phone: 334-280-1500 Fax: 334-280-1600 | |
Mrs. Nancy Suzannah Barnette, CRNP Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 7104 University Ct, Montgomery, AL 36117 Phone: 334-215-0711 Fax: 334-215-0710 | |
Julie B Sanders, CRNP Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 233 Winton Blount Loop, Montgomery, AL 36117 Phone: 334-270-5502 Fax: 334-270-5503 | |
Ms. Debra Phillips, MSN, AGCNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 300 Twining St, Montgomery, AL 36112 Phone: 334-953-7567 |